UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 198

Sortiert nach

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

The New England journal of medicine, 2006-02, Vol.354 (6), p.567-578

2006

Link zum Volltext

Verfügbarkeit prüfen

The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors

Annual review of medicine, 2004-01, Vol.55 (1), p.433-457

Rowinsky, Eric K

2004

Link zum Volltext

Verfügbarkeit prüfen

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

Clinical cancer research, 2009-01, Vol.15 (2), p.723-730

2009

Link zum Volltext

Verfügbarkeit prüfen

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

Blood, 2014-07, Vol.124 (3), p.385-392

2014

Link zum Volltext

Verfügbarkeit prüfen

IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor

Clinical cancer research, 2007-09, Vol.13 (18), p.5549s-5555s

2007

Link zum Volltext

Verfügbarkeit prüfen

A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer

Clinical cancer research, 2006-10, Vol.12 (19), p.5755-5763

2006

Link zum Volltext

Verfügbarkeit prüfen

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

Clinical cancer research, 2009-06, Vol.15 (12), p.4207-4212

2009

Link zum Volltext

Verfügbarkeit prüfen

Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy

Clinical cancer research, 2007-09, Vol.13 (18), p.5544s-5548s

2007

Link zum Volltext

Verfügbarkeit prüfen

Vascular Endothelial Growth Factor Receptor-1 in Human Cancer: Concise Review and Rationale for Development of IMC-18F1 (Human Antibody Targeting Vascular Endothelial Growth Factor Receptor-1)

Cancer, 2010-02, Vol.116 (4), p.1027-1032

2010

Link zum Volltext

Verfügbarkeit prüfen

Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors

Journal of clinical oncology, 2006-07, Vol.24 (19), p.2981-2984

Rowinsky, Eric K

2006

Link zum Volltext

Verfügbarkeit prüfen

THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS

Annual review of medicine, 1997-01, Vol.48 (1), p.353-374

Rowinsky, MD, Eric K

1997

Link zum Volltext

Verfügbarkeit prüfen

Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors

Clinical cancer research, 2008-10, Vol.14 (20), p.6663-6673

2008

Link zum Volltext

Verfügbarkeit prüfen

SL‐401 and SL‐501, targeted therapeutics directed at the interleukin‐3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia

British journal of haematology, 2014-09, Vol.166 (6), p.862-874

2014

Link zum Volltext

Verfügbarkeit prüfen

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

Oncogene, 2000-12, Vol.19 (56), p.6680-6686

2000

Link zum Volltext

Verfügbarkeit prüfen

A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies

Clinical cancer research, 2010-03, Vol.16 (6), p.1915-1923

2010

Link zum Volltext

Verfügbarkeit prüfen

Safety, pharmacokinetics, and pharmacodynamics in healthy Chinese volunteers treated with SC0062, a highly selective endothelin‐A receptor antagonist

Clinical and translational science, 2024-03, Vol.17 (3), p.e13750-n/a

2024

Link zum Volltext

Verfügbarkeit prüfen

Signal Events: Cell Signal Transduction and Its Inhibition in Cancer

The oncologist (Dayton, Ohio), 2003-12, Vol.8 (S3), p.5-17

Rowinsky, Eric K.

2003

Link zum Volltext

Verfügbarkeit prüfen

Rationale for the development of IMC‐3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet‐derived growth factor receptor α

Cancer, 2010-02, Vol.116 (S4), p.1018-1026

2010

Link zum Volltext

Verfügbarkeit prüfen

Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients

Clinical cancer research, 2010-11, Vol.16 (22), p.5591-5602

2010

Link zum Volltext

Verfügbarkeit prüfen

Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991–2001

JNCI : Journal of the National Cancer Institute, 2002-12, Vol.94 (24), p.1883-1888

2002

Link zum Volltext

Verfügbarkeit prüfen

mTOR Inhibition for Cancer Therapy: Past, Present and Future

1st ed. 2016, 2015

Link zum Volltext

Verfügbarkeit prüfen

A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer

Clinical cancer research, 2008-07, Vol.14 (14), p.4484-4490

2008

Link zum Volltext

Verfügbarkeit prüfen

Paclitaxel (Taxol)

The New England journal of medicine, 1995-04, Vol.332 (15), p.1004-1014

1995

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 198

Suche als RSS-Feed

Aktive Filter

KollektionIngenta

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(193)
Mit Volltextzugriff
(189)

Publikationsform

Sprache

Englisch
(198)
Japanisch
(22)

Erscheinungsjahr

n.n

Thema

Humans
(127)
Life Sciences & Biomedicine
(107)
Science & Technology
(107)
Biological And Medical Sciences
(98)
Medical Sciences
(98)
Oncology
(97)
Antineoplastic Agents
(93)
Pharmacology. Drug Treatments
(91)
Female
(72)
Male
(69)
Middle Aged
(68)
Adult
(67)
Aged
(65)
Neoplasms - Drug Therapy
(59)
Chemotherapy
(49)
Dose-Response Relationship, Drug
(41)
Antineoplastic Agents - Therapeutic Use
(29)
Drug Administration Schedule
(27)
Tumors
(26)
Antineoplastic Agents - Pharmacokinetics
(24)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors

Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent

IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor

A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer

A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies

Review: Monoclonal Antibodies to the Vascular Endothelial Growth Factor Receptor-2 in Cancer Therapy

Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells

Vascular Endothelial Growth Factor Receptor-1 in Human Cancer: Concise Review and Rationale for Development of IMC-18F1 (Human Antibody Targeting Vascular Endothelial Growth Factor Receptor-1)

Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors

THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS

Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors

SL‐401 and SL‐501, targeted therapeutics directed at the interleukin‐3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies

Safety, pharmacokinetics, and pharmacodynamics in healthy Chinese volunteers treated with SC0062, a highly selective endothelin‐A receptor antagonist

Signal Events: Cell Signal Transduction and Its Inhibition in Cancer

Rationale for the development of IMC‐3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet‐derived growth factor receptor α

Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients

Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991–2001

mTOR Inhibition for Cancer Therapy: Past, Present and Future

A Phase I and Pharmacokinetic Study of Lapatinib in Combination with Letrozole in Patients with Advanced Cancer

Paclitaxel (Taxol)

Aktive Filter

Suchergebnisse filtern